The latest news from academia, regulators
research labs and other things of interest
Posted: February 19, 2010
Liquidia Technologies Names Dr. Frank Malinoski as Chief Medical Officer
(Nanowerk News) Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that Frank J. Malinoski, M.D., Ph.D., has joined the company as Chief Medical Officer.
Dr. Malinoski has more than 20 years of executive experience in the biotech and pharmaceutical industries, including work in clinical development, regulatory evaluation and post-approval oversight for numerous vaccines and immunotherapy products. In his position, Dr. Malinoski will be responsible for clinical strategy and regulatory affairs across Liquidia’s product platform.
“We are extremely pleased to have Frank join our leadership team,” said Neal Fowler, Liquidia’s Chief Executive Officer. “Frank’s scientific expertise and impressive track record developing and commercializing successful vaccines will be invaluable as we advance our initial vaccine candidate through clinical trials and expand our pipeline of vaccine and therapeutic products.”
Dr. Malinoski brings to Liquidia an extensive background in the fields of vaccines, immunology, oncology, infectious disease and other key therapeutic areas. He has held senior positions in clinical research, business development and medical affairs at Wyeth, MedImmune, Nabi and several other biopharmaceutical companies. Dr. Malinoski began his career in the military, serving in clinical research and development of vaccines against infectious disease threats. Dr. Malinoski received his B.A. from Colby College, his M.D. from Albany Medical College and his Ph.D. in microbiology from Rutgers University.
Liquidia Technologies is developing precisely engineered particles for improved delivery of biological and small molecule therapeutics within the initial fields of vaccines, nucleic acid delivery and inhaled therapeutics. The ability to control particle design parameters such as size, shape and composition is allowing Liquidia to address critical unmet needs in the prevention and treatment of human disease. The company was founded in 2004 and is located in Research Triangle Park, North Carolina.